

# Virginia Department of Health: EVUSHELD Access Program

## The EVUSHELD Access Program:

The Virginia Department of Health developed the EVUSHELD Access Program to support Skilled Nursing Facilities with COVID-19 infection prevention by increasing access to EVUSHELD, a monoclonal antibody for COVID-19 pre-exposure prophylaxis. The program provides access to EVUSHELD via a mobile unit and VDH staff are available to support interested facilities in coordinating a site-visit. The program is **free of charge** for facilities and eligible nursing home patients and staff.

## How to participate in the program:

Please reach out to [COVID19Therapeutics@vdh.virginia.gov](mailto:COVID19Therapeutics@vdh.virginia.gov) to request an appointment.

## Eligibility:

EVUSHELD is a COVID-19 protective measure for adults who:

- ➔ Are not currently infected with the **SARS-CoV-2** virus and not recently exposed to an individual infected with **SARS-CoV-2**, **AND**
- ➔ Have moderate to severely compromised immune systems due to a medical condition or taking immunosuppressive medications and may not mount an adequate immune response to **COVID-19** vaccination, **OR**
- ➔ Have a history of severe adverse reactions to a **COVID-19** vaccine and/or component(s) of those vaccines, therefore vaccination with an available **COVID-19** vaccine is not recommended



## The EVUSHELD Mobile Unit

*VDH has contracted with Indelible Solutions, a consulting firm specializing in the advancement of health equity, to mobilize and administer EVUSHELD to eligible patients in nursing homes.*

*Indelible Solutions works with SnapNurse, an on-demand network of nurses. The EVUSHELD Access Program mobile team will consist of one Nurse Practitioner, Registered Nurse, and Certified Nursing Assistant.*

## Billing

**There is no cost for Nursing Homes to participate in this program.**

- **Patient(s) covered by Medicare/Medicaid:** Post treatment administration, the mobile vendor will bill Medicare/Medicaid for administration reimbursement.
- **Patient(s) NOT covered by Medicare/Medicaid:** Post treatment administration, the contractor will bill the VDH Central Office for all patients not covered under Medicare/Medicaid.

Administration	Components	
Administered as two consecutive intramuscular (IM) injections in the gluteal muscles. Repeat dose is recommended every 6 months.	1 vial of Tixagevimab 300 mg/3.0 mL (100 mg/mL) (dark grey cap)	1 vial of Cilgavimab 300 mg/3.0 mL (100 mg/mL) (white cap)
	NDC 0310-8895-01	NDC 0310-1061-01

*\*Patients who received the previously recommended dosage of 150 mg of tixagevimab and 150 mg of cilgavimab should receive an additional dosage of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible.*

To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below.



<http://www.evusheld.com>

Updated July 2022